Clinical Trial

Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a randomized, double-blind, multicenter, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of BEBT-209 in combination with fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer.
Trial Details
NCT Number NCT06998108
Lead Sponsor BeBetter Med Inc
Collaborators: Chinese Academy of Medical Sciences
Conditions HR+/HER2- Locally Advanced, Metastatic Breast Cancer
Enrollment 330 participants
Start Date 2022-06-09
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-31